Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 4
2004 7
2005 11
2006 11
2007 13
2008 5
2009 9
2010 7
2011 9
2012 12
2013 10
2014 12
2015 7
2016 12
2017 10
2018 8
2019 11
2020 11
2021 10
2022 7
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

170 results

Results by year

Filters applied: . Clear all
Page 1
Transforming the oncology data paradigm by creating, capturing, and retrieving structured cancer data at the point of care: A Mayo Clinic pilot.
Tevaarwerk AJ, Karam D, Gatten CA, Harlos ES, Maurer MJ, Giridhar KV, Haddad TC, Alberts SR, Holton SJ, Stockham A, Leventakos K, Hubbard JM, Mansfield AS, Halfdanarson TR, Chen R, Jochum JA, Schwecke AS, Eiring RA, Carroll JL, Riaz IB, McWilliams RR, Galanis E, Mandrekar SJ. Tevaarwerk AJ, et al. Among authors: alberts sr. Cancer. 2024 Apr 25. doi: 10.1002/cncr.35304. Online ahead of print. Cancer. 2024. PMID: 38662502
Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients.
Park HA, Edelmann D, Canzian F, Seibold P, Harrison TA, Hua X, Shi Q, Silverman A, Benner A, Macauda A, Schneider M, Goldberg RM, Alberts SR, Hoffmeister M, Brenner H, Chan AT, Peters U, Newcomb PA, Chang-Claude J. Park HA, et al. Among authors: alberts sr. Int J Cancer. 2023 Nov 1;153(9):1623-1634. doi: 10.1002/ijc.34663. Epub 2023 Aug 4. Int J Cancer. 2023. PMID: 37539667
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200.
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd. Giantonio BJ, et al. Among authors: alberts sr. J Clin Oncol. 2023 Jul 20;41(21):3670-3675. doi: 10.1200/JCO.22.02761. J Clin Oncol. 2023. PMID: 37459754
Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer.
McGarrah P, Hubbard J, Novotny PJ, Branda ME, Sargent DS, Morton RF, Fuchs CS, Benson AB, Williamson SK, Findlay BP, Alberts SR, Goldberg RM, Sloan JA. McGarrah P, et al. Among authors: alberts sr. Cancer Control. 2023 Jan-Dec;30:10732748231185047. doi: 10.1177/10732748231185047. Cancer Control. 2023. PMID: 37339926 Free PMC article.
Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma.
Tella SH, Foster N, Qian S, Nguyen T, Borad MJ, McWilliams RR, Alberts SR, Wee Ma W, Chakrabarti S, Fruth B, Wessling J, Hartgers M, Washburn L, Fernandez-Zapico ME, Hogenson TL, Pitot H, Jin Z, Mahipal A. Tella SH, et al. Among authors: alberts sr. Oncologist. 2023 Oct 3;28(10):917-e966. doi: 10.1093/oncolo/oyad144. Oncologist. 2023. PMID: 37339254 Free PMC article. Clinical Trial.
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Gallois C, Shi Q, Meyers JP, Iveson T, Alberts SR, de Gramont A, Sobrero AF, Haller DG, Oki E, Shields AF, Goldberg RM, Kerr R, Lonardi S, Yothers G, Kelly C, Boukovinas I, Labianca R, Sinicrope FA, Souglakos I, Yoshino T, Meyerhardt JA, André T, Papamichael D, Taieb J. Gallois C, et al. Among authors: alberts sr. J Clin Oncol. 2023 Feb 1;41(4):803-815. doi: 10.1200/JCO.21.02726. Epub 2022 Oct 28. J Clin Oncol. 2023. PMID: 36306483
Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma.
Gile JJ, Wookey V, Zemla TJ, Shi Q, Jin Z, Alberts SR, McWilliams RR, Ma WW, Borad M, Bekaii-Saab TS, Tran NH, Mahipal A. Gile JJ, et al. Among authors: alberts sr. Target Oncol. 2022 Sep;17(5):529-538. doi: 10.1007/s11523-022-00914-w. Epub 2022 Sep 2. Target Oncol. 2022. PMID: 36056231
Predictive Polygenic Score for Outcome after First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients Using Supervised Principal Component Analysis.
Park HA, Edelmann D, Canzian F, Harrison TA, Hua X, Shi Q, Silverman A, Schneider M, Goldberg RM, Alberts SR, Hoffmeister M, Brenner H, Chan AT, Peters U, Newcomb PA, Chang-Claude J. Park HA, et al. Among authors: alberts sr. Cancer Epidemiol Biomarkers Prev. 2022 Nov 2;31(11):2087-2091. doi: 10.1158/1055-9965.EPI-22-0320. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 35984985 Free PMC article. Clinical Trial.
Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial.
Sinicrope FA, Shi Q, Catteau A, Poage GM, Zemla TJ, Mlecnik B, Benson AB, Gill S, Goldberg RM, Kahlenberg MS, Nair SG, Shields AF, Smyrk TC, Galon J, Alberts SR. Sinicrope FA, et al. Among authors: alberts sr. JCO Precis Oncol. 2022 Aug;6:e2200010. doi: 10.1200/PO.22.00010. JCO Precis Oncol. 2022. PMID: 35952316 Free PMC article. Clinical Trial.
170 results